Guidance on the management of diarrhoea during cancer chemotherapy

The Lancet Oncology

Volumn 15, Issue 10, 2014, Pages

  Andreyev, Jervoise ^a   Ross, Paul ^b   Donnellan, Clare ^c   Lennan, Elaine ^d   Leonard, Pauline ^e   Waters, Caroline ^f   Wedlake, Linda ^a   Bridgewater, John ^g   Glynne Jones, Rob ^h   Allum, William ^a   Chau, Ian ^a   Wilson, Richard ⁱ   Ferry, David ^j  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e WHITTINGTON HOSPITAL NHS TRUST   (United Kingdom)

^f Pharmacy Kent and Medway Cancer Network   (United Kingdom)

^g UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^h MOUNT VERNON CANCER CENTRE   (United Kingdom)

ⁱ BELFAST CITY HOSPITAL   (United Kingdom)

^j NEW CROSS HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR; FIRTECAN; FIRTECAN GLUCURONIDE; FLUOROURACIL; FOLINIC ACID; IPILIMUMAB; IRINOTECAN; LOPERAMIDE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; OCTREOTIDE; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; ANTIDIARRHEAL AGENT; ANTINEOPLASTIC AGENT;

ABDOMINAL RADIOGRAPHY; BACTERIAL OVERGROWTH; BILE ACID MALABSORPTION; BLOOD SAMPLING; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DAILY LIFE ACTIVITY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; FECES CULTURE; FLUID RESUSCITATION; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL ENDOSCOPY; GILBERT DISEASE; HUMAN; IMMUNE DEFICIENCY; LACTOSE INTOLERANCE; MEDICAL HISTORY; NONHUMAN; PATIENT COUNSELING; PATIENT EDUCATION; PHYSICAL EXAMINATION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STEATORRHEA; STOMACH MUCOSA LESION; CHEMICALLY INDUCED; FEMALE; FLUID THERAPY; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PRACTICE GUIDELINE; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIDIARRHEALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DIARRHEA; FEMALE; FLUID THERAPY; HUMANS; MALE; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84906824476     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70006-3     Document Type: Review

References (100)

1. Saltz LB, Douillard JY, Pirotta N, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001, 6:81-91.
2. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20:2812-2823.
3. Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005, 16:549-557.
4. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25:1670-1676. the Gruppo Oncologico Nord Ovest.
5. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25:4779-4786.
6. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019.
7. Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012, 30:1755-1762.
8. Benson AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004, 22:2918-2926.
9. Kornblau S, Benson AB, Catalano R, et al. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage 2000, 19:118-129.
10. Dunberger G, Lind H, Steineck G, et al. Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls. Eur J Cancer 2010, 46:606-615.
11. Richardson G, Dobish R Chemotherapy induced diarrhea. J Oncol Pharm Pract 2007, 13:181-198.
12. Gibson RJ, Keefe DM Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 2006, 14:890-900.
13. Andreyev HJN, Davidson SE, Gillespie C, Allum WH, Swarbrick E Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut 2012, 61:179-192. the British Society of Gastroenterology, the Association of Colo-Proctology of Great Britain and Irelandthe Association of Colo-Proctology of Great Britain and Ireland, the Association of Upper Gastrointestinal Surgeonsthe Association of Upper Gastrointestinal Surgeons, the Faculty of Clinical Oncology Section of the Royal College of Radiologiststhe Faculty of Clinical Oncology Section of the Royal College of Radiologists.
14. Malet-Martino M, Martino R Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002, 7:288-323.
15. Zalcberg J, Kerr D, Seymour L, Palmer M Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Eur J Cancer 1998, 34:1871-1875. the Tomudex International Study Group.
16. McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 2002, 94:1160-1167.
17. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 2004, 22:648-657.
18. Diasio RB, Beavers TL, Carpenter JT Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988, 81:47-51.
19. Raida M, Schwabe W, Häusler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 2001, 7:2832-2839.
20. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008, 26:2131-2138. the German 5-FU Toxicity Study Group.
21. Ezzeldin HH, Diaiso RB Predicting fluorouracil toxicity: can we finally do it?. J Clin Oncol 2008, 26:2080-2082.
22. Dahan L, Ciccolini J, Evrard A, et al. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications. J Clin Oncol 2012, 30:e41-e44.
23. Loganayagam A, Arenas Hernandez M, Corrigan A, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 2013, 108:2505-2515.
24. Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995, 13:210-221.
25. Masi G, Falcone A, Di Paolo A, et al. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. Clin Cancer Res 2004, 10:1657-1663.
26. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003, 18:1095-1100.
27. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Keefe DM Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther 2008, 7:1919-1925.
28. Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998, 16:2745-2751.
29. de Jong FA, Kehrer DF, Mathijssen RH, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 2006, 11:944-954.
30. Swami U, Goel S, Mani S Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. Curr Drug Targets 2013, 14:777-797.
31. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002, 2:43-47.
32. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004, 22:1382-1388.
33. Di Paolo A, Bocci G, Polillo M, et al. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr Drug Metab 2011, 12:932-943.
34. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
35. Fabian MA, Biggs WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23:329-336.
36. Keefe D, Anthony L Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care. Curr Opin Support Palliat Care 2008, 2:19-21.
37. Bowen JM Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care 2013, 7:162-167.
38. Wedlake LJ, Thomas K, Lalji A, et al. Predicting late effects of pelvic radiotherapy: is there a better approach?. Int J Radiat Oncol Biol Phys 2010, 78:1163-1170.
39. Gibson RJ, Keefe DM, Lalla RV, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2013, 21:313-326. the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).
40. Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3342-3350.
41. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006, 24:2283-2289.
42. Pagès C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 2013, 23:227-230.
43. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114. the MRC COIN Trial Investigators.
44. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012, 30:3499-3506.
45. Sonis ST Regimen-related gastrointestinal toxicities in cancer patients. Curr Opin Support Palliat Care 2010, 4:26-30.
46. Fuccio L, Guido A, Andreyev HJN Management of intestinal complications in patients with pelvic radiation disease. Clin Gastroenterol Hepatol 2012, 10:1326-1334. e4.
47. Ishihara S, Watanabe T, Akahane T, et al. Prognostic significance of adverse events associated with preoperative radiotherapy for rectal cancer. Int J Colorectal Dis 2011, 26:911-917.
48. Kozelsky TF, Meyers GE, Sloan JA, et al. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol 2003, 21:1669-1674. the North Central Cancer Treatment Group.
49. Martenson JA, Halyard MY, Sloan JA, et al. Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA. J Clin Oncol 2008, 26:5248-5253.
50. Andreyev HJN, Vlavianos P, Blake P, Dearnaley D, Norman AR, Tait D Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist?. Int J Radiat Oncol Biol Phys 2005, 62:1464-1471.
51. Andreyev HJN A physiological approach to modernize the management of cancer chemotherapy-induced gastrointestinal toxicity. Curr Opin Support Palliat Care 2010, 4:19-25.
52. Parnes HL, Fung E, Schiffer CA Chemotherapy-induced lactose intolerance in adults. Cancer 1994, 74:1629-1633.
53. Osterlund P, Ruotsalainen T, Peuhkuri K, et al. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2004, 2:696-703.
54. Pearson AD, Craft AW, Pledger JV, Eastham EJ, Laker MF, Pearson GL Small bowel function in acute lymphoblastic leukaemia. Arch Dis Child 1984, 59:460-465.
55. Pettoello-Mantovani M, Guandalini S, di Martino L, et al. Prospective study of lactose absorption during cancer chemotherapy: feasibility of a yogurt-supplemented diet in lactose malabsorbers. J Pediatr Gastroenterol Nutr 1995, 20:189-195.
56. Khoshini R, Dai SC, Lezcano S, Pimentel M A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008, 53:1443-1454.
57. Maringhini A, Gertz MA, DiMagno EP Exocrine pancreatic insufficiency after allogeneic bone marrow transplantation. Int J Pancreatol 1995, 17:243-247.
58. Smith GM, Chesner IM, Asquith P, Leyland MJ Small intestinal bacterial overgrowth in patients with chronic lymphocytic leukaemia. J Clin Pathol 1990, 43:57-59.
59. Bustillo I, Larson H, Saif MW Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer. JOP 2009, 10:576-578.
60. Stringer AM, Gibson RJ, Logan RM, et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) 2009, 234:430-441.
61. Grace E, Shaw C, Whelan K, Andreyev HJ small intestingal bacterial overgrowth-prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 2013, 38:674-688.
62. Sanders JE Chronic graft-versus-host disease and late effects after hematopoietic stem cell transplantation. Int J Hematol 2002, 76(suppl 2):15-28.
63. Papadopoulou A, Lloyd DR, Williams MD, Darbyshire PJ, Booth IW Gastrointestinal and nutritional sequelae of bone marrow transplantation. Arch Dis Child 1996, 75:208-213.
64. Grigg AP, Angus PW, Hoyt R, Szer J The incidence, pathogenesis and natural history of steatorrhea after bone marrow transplantation. Bone Marrow Transplant 2003, 31:701-703.
65. Cascinu S, Bichisao E, Amadori D, et al. High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. Support Care Cancer 2000, 8:65-67.
66. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G 5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study. J Chemother 1991, 3:51-54.
67. Chambers P, Daniels SH, Thompson LC, Stephens RJ Chemotherapy dose reductions in obese patients with colorectal cancer. Ann Oncol 2012, 23:748-753.
68. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012, 30:1553-1561. the American Society of Clinical Oncology.
69. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2099-2105.
70. Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 2008, 113:2704-2713. the Burden of Illness Head and Neck Writing Committee.
71. Mort D, Landsdown M, Smith N, Protopapa K, Mason M For Better, for worse? A review of the care of patients who died within 30 days of receiving systemic anti-cancer therapy 2008, National Confidential Enquiry into Patient Outcome and Death, London.
72. Chemotherapy services in England: ensuring quality and safety 2009, National Chemotherapy Advisory Group, for the Department of Healthfor the Department of Health, National Cancer Action Team, London.
73. Common terminology criteria for adverse events (CTCAE) version 4.0 US Department of Health and Human Services, (accessed Jan 14, 2014). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
74. Ahlberg K, Ekman T, Gaston-Johansson F The experience of fatigue, other symptoms and global quality of life during radiotherapy for uterine cancer. Int J Nurs Stud 2005, 42:377-386.
75. Jakobsson S, Ahlberg K, Taft C, Ekman T Exploring a link between fatigue and intestinal injury during pelvic radiotherapy. Oncologist 2010, 15:1009-1015.
76. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011, 60:571-607. the IBD Section of the British Society of Gastroenterology.
77. Thomas PD, Forbes A, Green J, et al. Guidelines for the investigation of chronic diarrhoea, 2nd edn. Gut 2003, 52:v1-15.
78. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377. the Early Goal-Directed Therapy Collaborative Group.
79. Powell-Tuck J, Gosling P, Lobo DN, et al. British Consensus guidelines on intravenous fluid therapy for adult surgical patients (accessed Jan 14, 2014). http://www.bapen.org.uk/pdfs/bapen_pubs/giftasup.pdf.
80. Weintraub HS, Killinger JM, Heykants J, Kanzler M, Jaffe JH Studies on the elimination rate of loperamide in man after administration of increasing oral doses of Imodium. Curr Ther Res 1977, 21:867-878.
81. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000, 68:231-237.
82. Remington M, Fleming CR, Malagelada JR Inhibition of postprandial pancreatic and biliary secretion by loperamide in patients with short bowel syndrome. Gut 1982, 23:98-101.
83. Nightingale JM, Lennard-Jones JE, Walker ER A patient with jejunostomy liberated from home intravenous therapy after 14 years; contribution of balance studies. Clin Nutr 1992, 11:101-105.
84. Cooper AM, Braatvedt GD, Qamar MI, et al. Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man. Clin Sci (Lond) 1991, 81:169-175.
85. Wadler S, Haynes H, Wiernik PH Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 1995, 13:222-226.
86. Cascinu S, Fedeli A, Fedeli SL, Catalano G Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993, 11:148-151.
87. Topkan E, Karaoglu A Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. Oncology 2006, 71:354-360.
88. Zachariah B, Gwede CK, James J, et al. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst 2010, 102:547-556.
89. Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994, 86:446-449.
90. Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993, 4:443-445.
91. Goumas P, Naxakis S, Christopoulou A, Chrysanthopoulos C, Nikolopoulou V, Kalofonos HP Octreotide Acetate in the Treatment of Fluorouracil-Induced Diarrhea. Oncologist 1998, 3:50-53.
92. Johansson C, Efendic S, Wisén O, Uvnäs-Wallensten K, Luft R Effects of short-time somatostatin infusion on the gastric and intestinal propulsion in humans. Scand J Gastroenterol 1978, 13:481-483.
93. Karthaus M, Ballo H, Abenhardt W, et al. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 2005, 68:326-332.
94. Lenfers BH, Loeffler TM, Droege CM, Hausamen TU Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999, 10:1251-1253.
95. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009, 15:5591-5598.
96. Hyatt JL, Tsurkan L, Morton CL, et al. Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11. Chem Biol Interact 2005, 157-158:247-252.
97. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001, 19:3801-3807.
98. Gafter-Gvili A, Fraser A, Paul M, Leibovici L Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005, 142:979-995.
99. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006, 107:1743-1751.
100. Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999, 94:1327-1331.